The Street Reports
“2023 Stock to Watch”
Stock Quote: OTC: HALB
The Street Reports Podcast, News Coverage Listen and Look Now!
Halberd Testing Protocol “Approved” at Mississippi State University (MSU)
“The Street Reports Podcasts” HALB’s CEO, CTO and YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., Listen Now!
Coverage Initiated: Strong Buy Recommended
‘We’re that close’: to cure big diseases @ YSU, William Hartman, CEO
Halberd Corporation’s (OTC: HALB) is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company’s extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases Our patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing. To treat the specific disease, the appropriate treatment process is applied to the fluid. This can include exposure to radio frequency or laser irradiation or chemical bonding to kill or trap the target disease antigens. The cleansed fluid is then returned to the patient. See additional information, now! Research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. Listen to News Broadcast now!
News And Headlines
May 9, 2023 Halberd Testing Protocol “Approved” at Mississippi State University (MSU)
May 2, 2023 Halberd (HALB) Pursuing a Nasal Spray to Counteract Neurodegenerative Conditions and the Effects of Head Trauma
April 25, 2023 Halberd Corporation 1Q 2023 CEO Letter
April 21, 2023 “The Street Reports Podcasts” HALB’s CEO, CTO and YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., Listen Now!
April 17, 2023 Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
April 11, 2023 Halberd Begins Preclinical Testing at Mississippi State University (MSU)
April 3, 2023 Halberd’s Successful CDC Meeting Leads to Expanded Testing of Antibiotic Resistant Pathogens
March 30, 2023 Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma
March 21, 2023 Halberd Eradicates All Strains of Antibiotic-Resistant E. Coli Provided by the CDC at Youngstown State University YSU
March 14, 2023 Halberd Corp & Centers of Disease Control (CDC) to Discuss Results at Youngstown State University (YSU)
February 21, 2023 Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
February 13, 2023 Halberd Corp Announces Breakthrough in Candida auris Treatment
February 8, 2023 Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria at Youngstown State University (YSU)
January 31, 2023 Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma Tests to be scheduled at Mississippi State University
January 3, 2023 Halberd Corporation CEO Letter 2022 Achievements and 2023 Goals
December 6, 2022 Halberd Receives Antibiotic Resistant Bacteria from The Centers of Disease Control (CDC) for Laser Eradication
December 5, 2022 “The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!
November 17, 2022 Halberd Corporation Eradicates Cancer Disease Antigen Linked to Breast Cancer All Five of The Top Cancer Disease Antigens “Eliminated”
November 14, 2022 Halberd Signs Worldwide Agreement for Medications & Nutraceuticals
October 27, 2022 Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast Listen Now!
October 18, 2022 Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minute Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases
October 12, 2022 Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum
September 28, 2022 Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment
August 30, 2022 Halberd Corp Featured on Proactive Investors Watch Now!
August 23, 2022 Halberd Demonstrates Precise Control of Key Cancer T-Cell Protein
August 4, 2022 NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology
July 28, 2022 Halberd CEO Discusses OTCQB Uplisting/Proprietary Technologies on Stock Day
July 20, 2022 Halberd Corp. Launches “Halberd Cancer Therapeutics” Wholly Owned Subsidiary; Seeking Alpha Reports Halberd launches “Halberd Cancer Therapeutics” wholly owned subsidiary
July 14, 2022 Halberd’s Antibody Effective Against 4 SARS-CoV-2 Mutations, Including Omicron
July 12, 2022 Halberd Corporation Update, CEO Letter and 2022 Expectations
June 22, 2022 Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer; Seeking Alpha Reports Halberd launches subsidiary to focus on cancer treatment; Street Signals Reports Halberd Corporation Creates Subsidiary for Patented Technology to Treat Cancer
June 8, 2022 Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification
May 24, 2022 Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines
May 18, 2022 Halberd Engages Professional Firm to Proceed with FDA Filings
May 12, 2022 Halberd Audited Financials; Files Form-10 as First Step to Up-list to OTCQB
April 25, 2022 Halberd CEO Letter Q1 Accomplishments and 2022 Outlook
April 18, 2022 Halberd Eliminates E. Coli in 20 Minutes vs. 7-10 Days w/Conventional Antibiotics
April 11, 2022 Halberd Entering the Medical Metaverse
April 4, 2022 Halberd In-Vitro Successes Elimination of Protein Linked to Depression
March 16, 2022 Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans
March 8, 2022 Halberd Expands Its Technical Expertise w/the Addition of Microbiology Professor
March 1, 2022 Halberd’s COVID-19 Antibody is the Only One in Competitive Tests to Bind to Omicron Variant Outperforms Approved COVID Antibodies
February 22, 2022 Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
February 8, 2022 Halberd Eliminates 100% of Tau Protein – The 9th of 10 Target Neurodegenerative Disease Antigens Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases
February 1, 2022 Halberd Achieves Landmark Selective Elimination of Tau from an Antigen Mixture Tau has been shown to be important in the development of Alzheimer’s Disease. Eradication of tau accomplished without reducing levels of non-target cytokine
January 25, 2022 Halberd CEO Letter: 2021 Year-End & 2022 Outlook
January 13, 2022 Halberd Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
January 5, 2022 Halberd Corporation Now an Official US Government Contractor
December 20, 2021 Halberd Moves Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid
December 15, 2021 Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort to Eliminate Neurodegenerative Diseases
December 13, 2021 Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
December 6, 2021 Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE
November 22, 2021 Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer’s Disease
November 8, 2021 Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
November 2, 2021 GTX Corp Begins Selling Vita-Shield-Max Immune Support Nutraceutical
November 1, 2021 Halberd Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
October 25, 2021 Halberd Files Provisional Patent on Breakthrough Obesity Treatment
October 20, 2021 Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure
October 12, 2021 Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
October 7, 2021 Halberd Corporation CEO Letter Q3-21 Accomplishments and Q4 Plans
October 5, 2021 Halberd’s VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
September 22, 2021 Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
September 13, 2021 Halberd’s Treatment Eradicates Primary Building Block of Alzheimer’s Disease
September 8, 2021 Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions
August 30, 2021 Halberd Alzheimer’s Testing at YSU & ASU Yield Outstanding Results
August 25, 2021 Halberd Receives Patent for Treatment of Cockayne Syndrome – May Provide Pathway to Slow Aging
August 23, 2021 Halberd Files Patent Application – Furthering Efforts on Alzheimer’s Disease
August 18, 2021 Halberd Corp. VITA-SHIELD-MAX(TM) Available – Buy Now!
August 16, 2021 Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
August 11, 2021 Halberd Corporation Expands Medical Team Appoints “Nephrologist” for Blood-Borne Disease(s)
August 9, 2021 Halberd Corporation’s Vita-Shield-MaxTM Immunity Support Product Shipped
July 28, 2021 Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished” A Major Step towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s, PTSD and CTE
July 22, 2021 Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/CTE
July 6, 2021 Halberd Corporation CEO Letter Update & Plans
June 30, 2021 Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
June 21, 2021 Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
June 16, 2021 Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy
June 9, 2021 Halberd Corporation Undertakes Process toward the Elimination of Alzheimer’s Disease
June 7, 2021 Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies Demonstrates Greater Binding Affinity than Previous Antibodies
May 25, 2021 Halberd Corp Successfully Conjugates Metallic Particles and E. Coli Antibody
May 19, 2021 “MarketWatch” Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
May 17, 2021 Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody
May 13, 2021 Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease at Youngstown University (YSU)
May 10, 2021 Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications
May 4, 2021 Halberd Corporation Appoints New Chief Technical Officer to Optimize Radio Frequency and Laser Eradication of Disease
April 26, 2021 Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser
April 21, 2021 Halberd Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations
April 19, 2021 Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward with the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus Brings Critical Radio Frequency Wave Expertise to Company’s Effort
April 12, 2021 Halberd Files International Patent Cooperation Treaty
April 6, 2021 Halberd Corporation CEO Letter 2020-Q1-21 Accomplishments and Q2 Plans
March 30, 2021 Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens Paves Way for Disease Elimination by Radio Frequency Waves
March 23, 2021 Halberd Corporation Completes Compilation of Medical Articles in Support of Nutraceuticals in Their VITA-SHIELD-MAXTM Immune Booster
March 18, 2021 Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies
March 16, 2021 Halberd Corporation’s VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Now In Production
March 11, 2021 Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark for Immunity Boosting Nutraceutical
March 9, 2021 Halberd’s CEO on The Stock Day Podcast Breaking Down 20X Neutralizing Affinity SARS-COV-2 Antibody
March 8, 2021 Epidemiologic Solutions Corporation (ESC), an IRS Approved, Qualified Public Charity, Announces Its Commitment of $2,000,000 to Halberd Corporation Research Endeavors (HALB), as Its Initial Step Toward Eradicating Disease
March 2, 2021 Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater
February 16, 2021 Halberd Collaborates with GreenBioAZ, Inc. for the Development of its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens
January 29, 2021 Halberd Corporation on MoneyTV Discussing COVID-19 Breakthroughs
January 28, 2021 HALB’s CEO on Stock Day Discusses Breakthrough COVID-19 Diagnostic
January 25, 2021 Halberd Corporation’s Research Breakthrough – Qualitative & Quantitative Measurement of Covid-19 Antigens and/or Antibodies
January 12, 2020 Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article
January 4, 2020 Halberd Corporation 2020 Year End CEO Letter
The Street Now is a leading publisher of today’s market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. We have been paid cash only for this report. We do not take shares in payment for our work.
A complete disclaimer can be viewed HERE
Statements & Policies
We never take shares as payment for our services. We are paid cash in advance of our initiating our marketing service for any company. We base any target price in conjunction with technical analysis and company management fore-knowledge and input.
Summary of Disclosures
- You should review the entirety of the following Statements & Policies, which include important information not included in this Summary of Disclosures. You should not rely solely on this summary.
- By accessing The Street Now (hereinafter referred to as “The Street Now” “we,” “us,” or “our”) website, you agree that you have reviewed and agree to the following Statements & Policies. If you do not agree to these Statements & Policies, you may not use the The Street Now website.
- The Street Now provides readers with information regarding publicly traded companies that have retained The Street Now to provide advertising, news and public relations services on their behalf. The Street Now receives compensation from the companies in the form of cash. The Street Now is neither an investment adviser nor a broker-dealer. The information presented in The Street Now’s website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. None of the information provided through this website constitutes a recommendation. Please consult with an independent investment adviser or other financial adviser before making an investment decision.
- The opinions and analysis included in this website are based on factual information obtained from public filings and other sources deemed to be reliable and are provided “as is” in good faith, but no representation or warranty, expressed, implied, or statutory, is made as to the accuracy or completeness of such information, which may be subject to change without notice.
- The Street Now and its owners, officers, directors, employees and affiliates may own, or may buy and sell, securities of companies profiled on the The Street Now’s website at any time before, during, or after distribution of information on the companies by The Street Now
Safe Harbor Statement
This website includes forward-looking statements pertaining to future anticipated plans, performance and development of the companies on whose behalf we disseminate information. Any statements on this website that are not statements of historical fact should be considered forward-looking statements. These forward-looking statements generally can be identified by phrases such as “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” “intends,” or other words or phrases of similar import. Similarly, statements in this website that describe a company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward–looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
By accessing The Street Now’s website, you signify your agreement to these Statements & Policies. If you do not agree to these Statements & Policies, you may not use The Street Now’s website. We reserve the right, at our sole discretion, to change, modify, add or delete portions of these Statements & Policies at any time. The Street Now’s website may contain many links to other websites, including paid advertisements, whose content is not managed by The Street Now. We do not endorse, nor are we responsible for, any of the content of those external websites.
All rights, including copyright, in the content of the The Street Now’s website are owned or controlled for these purposes by The Street Now. In accessing The Street Now’s website, you agree that you may only download and/or view the content for your own personal, non-commercial use. Except where expressly stated otherwise, without the prior written permission of The Street Now, you are not permitted to copy, broadcast, download, store (in any medium), transmit, show or play in public, adapt or change in any way the content of The Street Now’s website for any other purpose whatsoever.
This notice applies to all information collected or submitted on The Street Now’s website. On some pages, you can make requests and register to receive materials. The types of personal information collected at these pages are:
- Email address
- Phone number(s)
The Way We Use Information
We use the information you provide about yourself when responding to your requests for specific information. We occasionally share this information with outside parties we believe you would find of interest. We may be compensated by such parties for this service. We use return email addresses to answer the email we receive. You can register with our website if you would like to receive our periodic mailings as well as updates on our new products and services. Information you submit on our website will not be used for this purpose unless you fill out the registration form. We use non-identifying and aggregate information to better design our website and to share with advertisers. For example, we may tell an advertiser that X number of individuals visited a certain area on our website, or that Y number of men and Z number of women filled out our registration form. Finally, we never use or share the personally identifiable information provided to us online in ways unrelated to those described above without also providing you an opportunity to opt-out or otherwise prohibit such unrelated uses.
Our Commitment To Data Security
To prevent unauthorized access, maintain data accuracy, and ensure the correct use of information, we have put in place what we believe are appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online. However, we make no guarantees or representations that such procedures will be effective and that all information will remain secure under all circumstances.
Our Commitment To Children’s Privacy
Protecting the privacy of children is especially important. For that reason, we never collect or maintain information at our website from individuals we actually know are under the age of 13, and no part of our website is structured to attract anyone under the age of 13.
How You Can Access or Correct Your Information
You can access all your personally identifiable information that we collect online and maintain by editing your user profile. We use this procedure to better safeguard your information. You can correct factual errors in your personally identifiable information by sending us a request that credibly shows error. To protect your privacy and security, we will also take reasonable steps to verify your identity before granting access or making corrections.
The Street Now “Tip of the Day” Disclaimer
The Street Now is not a registered investment advisor. The information contained on this site is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented on this recorded line is provided for informational purposes only and is not to be treated as advice to make any specific investment. Please consult with an independent investment advisor before making an investment decision. Neither The Street Now nor its officers, directors, partners, employees, consultants nor anyone involved in this site is a registered investment adviser or broker/dealer and none of the foregoing make any recommendation that the purchase of securities of any company profiled on this site is suitable or advisable for any person or that an investment in such securities will be profitable. Past performance of profiled securities is not indicative of future results. Companies profiled on this site line may lack an active trading market for their securities and investing in such securities is highly speculative and carries a high degree of risk. Anyone investing in these companies should be able and prepared to bear a loss of his or her entire investment.
The Street Now Rating Disclaimer
The Street Now strives to ensure that all content and information published at this web site is current and accurate. The information and ratings at The Street Now does not in any way constitute legal or professional advice and The Street Now cannot be held liable for actions arising from its use. These ratings are based on The Street Now opinion ONLY and these ratings are NOT a recommendation to BUY and or SELL any SEC regulated public company. In addition The Street Now cannot be held responsible for the contents of any externally linked pages. Reference within this site to any specific commercial or non-commercial company, newsletter, product, process, or service by trade name, trademark, or otherwise does not constitute or imply an endorsement, recommendation, or favoring by The Street Now.
The Street Now Educational Resources Disclaimer
Online Broker Reviews are provided for general information purposes only and should not be considered an individualized recommendation or advice.
The Street Now DOES NOT receive any compensation from any of the online brokerage firms reviewed in this Educational Resources – Online Broker Reviews.
Email and Instant Message Policy
Information Regarding Securities and Market Data. The Street Now does not guarantee any information regarding securities issues and market data contained in an email to or from its employees, agents, or affiliates.
Email and Instant Message (IM) Security. The Street Now is not responsible for any damages resulting from a third party intercepting or otherwise obtaining an email, or the information contained within an email, sent to or from The Street Now, its employees, agents, or affiliates. For your protection, do not include account numbers, social security numbers, credit card numbers, passwords or any other non-public information in your email or IM.
Monitoring and Confidentiality of Email and Instant Messaging (IM). The Street Now may monitor email and IM communications addressed to the firm and any of its employees. The Street Now reserves the right to monitor such communications and does not guarantee the confidentiality of any transmission.
The Street Now’s website provides readers with information regarding publicly traded companies that have retained The Street Now to provide advertising, news and public relations services on their behalf. The Street Now receives compensation from the companies or affiliates in the form of cash only and do not except securities for conpensation. Such compensation, especially compensation in the form of securities, may create an actual or potential conflict of interest. In addition, to the extent that parties, including the companies discussed, investors or others, further disseminate content or other statements provided by The Street Now, such parties operate outside of The Street Now’s control. Such further dissemination may not be accompanied by appropriate disclaimers or other disclosures, and The Street Now assumes no responsibility for any such statements or dissemination.
Because The Street Now receives compensation for disseminating information, we may have a conflict of interest in terms of disseminating negative information about the companies that retain us. Readers should consider this in reaching their independent decision as to how to use the information contained in The Street Now’s website.
It is the practice of The Street Now to sell all securities received as compensation upon the expiration of the applicable holding period set forth in Rule 144 under the Securities Act of 1933 (Rule 144), notwithstanding the fact that The Street Now may be advertising or distributing materials on such securities and their issuers at the time of the sale of such securities. More generally, The Street Now may sell any securities that it holds at any time that it legally may do so, as it deems appropriate.
In addition, writers and editors who provide or review content contained on The Street Now’s website may buy, sell or maintain positions in securities of the companies discussed on The Street Now’s website. Such trading, which necessarily reflects an individual’s personal resources and financial condition, may be inconsistent with statements on The Street Now’s website.
Neither The Street Now nor its officers, directors, partners, employees, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker/dealer and none of the foregoing make any recommendation that the purchase of securities of any company profiled in the The Street Now’s website is suitable or advisable for any person or that an investment in such securities will be profitable. The information contained in the The Street Now’s website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the The Street Now’s website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser before making an investment decision.
The opinions and analysis included in this website are based on factual information obtained from public filings and other sources deemed to be reliable and are provided “as is” in good faith, but no representation or warranty, expressed, implied, or statutory, is made as to the accuracy or completeness of such information, which may be subject to change without notice. The Street Now shall not be liable for any errors or any actions taken in reliance thereon. Statements of opinion and belief are those of the authors and/or editors of this website, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that The Street Now or such authors or editors have any special or greater knowledge about the companies profiled or any particular expertise in the industries or markets in which the profiled companies operate and compete.
Factual information on this website is obtained from public filings and other sources deemed to be reliable; however, The Street Now takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Certain statements included in this website may be forward-looking statements based on current expectations. The Street Now makes no representation and provides no assurance or guaranty that such forward -looking statements will prove to be accurate. Persons using the The Street Now website are urged to consult with independent financial advisers with respect to an investment in any company profiled herein. Investors should independently verify information provided in the The Street Now’s website by completing their own due diligence on any company in which they are contemplating an investment and review a complete information package on that company, which should include, but not be limited to, the company’s annual reports, quarterly reports, press releases, and regulatory filings.
Past performance of profiled securities is not indicative of future results. Companies profiled in this website may lack an active trading market for their securities and investing in such securities is highly speculative and carries a high degree of risk. Anyone investing in these companies should be able and prepared to bear a loss of his or her entire investment. The information on this website is not designed to be used as the sole basis for an investment decision. Persons using the The Street Now’s website should confirm to their own satisfaction the veracity of any information prior to entering into any investment. The decision to buy or sell any security of a company that may be featured by The Street Now is done purely at the reader’s own risk. Under no circumstances will The Street Now owners, officers, directors, partners, employees, consultants or other persons involved in the publication of this website be held liable for any losses incurred by the use of information contained in this website.
The Street Now and its owners, officers, directors, employees and affiliates may own, or may buy and sell, securities of companies profiled in this website at any time before, during, or after distribution of information on the companies by The Street Now. The Street Now and its employees and affiliates may profit in the event the shares of the companies increase in value. Such securities may be sold from time to time even after The Street Now has distributed positive information regarding the companies. The Street Now does not guarantee that it will purchase the securities of profiled companies. The Street Now has no obligation to inform readers of its trading activities or the trading activities of any of its employees and/or affiliates.
The Street Now from time to time enters into agreements to purchase securities of publicly traded companies to provide financing to these companies.
The content published on this website is intended for and only to be used for reference purposes and is neither an offer nor a solicitation to purchase or sell any security or instrument or to participate in any particular trading strategy. None of the information provided through this website constitutes a recommendation that any investment or trading strategy is suitable for any person. Persons should consult with their financial advisers before making any investment decisions.
THERE CAN BE NO ASSURANCE THAT THE CONTENT PUBLISHED ON THIS SITE IS ACCURATE OR WITHOUT ERROR. ANY PERSON WHO MAKES USE OF SUCH CONTENT EXPRESSLY ASSUMES ALL RISKS FROM USING THE CONTENT. In particular, The Street Now does not guarantee it reviews, and is not responsible for confirming, the accuracy of issuer documents and information submitted for inclusion on this site. The issuer and its management are primarily responsible for the accuracy of any information regarding the issuer provided on this site. INVESTORS ARE STRONGLY ADVISED TO CONFIRM THE ACCURACY OF ANY INFORMATION OBTAINED FROM THIS SITE PRIOR TO MAKING ANY INVESTMENT DECISION.
Because many securities traded over-the-counter (OTC) are relatively illiquid, or “thinly traded,” which tends to increase volatility in market prices, an investment in an OTC security involves a high degree of risk. These speculative and illiquid securities are often difficult for investors to buy or sell without significantly affecting the quoted price. It should be noted that the liquidation of a position in an OTC security may not even be possible within a reasonable period of time.
Dependable information regarding issuers of OTC securities, their prospects, or the risks associated with the business of any particular issuer or an investment in the issuer’s securities may not be available. For this reason, it may be difficult to properly value an investment in an OTC security or accurately determine the risks involved with investing in such a security.
Issuers of OTC securities quoted on the OTC Link system are not required to provide any kind of information to investors. While many issuers register OTC securities with the Securities and Exchange Commission (SEC) and regularly provide reports to investors in connection with such registration, they are not required to continue such registration or regularly provide such reports because their securities are quoted on OTC Link. Securities may continue to be quoted on the OTC Link system if issuers are delinquent in their reporting obligation to the SEC or other federal or state regulatory agencies. Quotation of a security on the OTC Link system or the Yellow Sheets does not in itself create any ongoing filing or reporting obligations with the SEC for any issuer. In fact, issuers may not even be aware that their securities are quoted on the OTC Link system.
The Street Now’s website may contain articles and other content submitted by third parties, including, but not limited to, articles submitted through the The Street Now Premium Partnership Program. The opinions and other statements expressed by such third parties are theirs alone and do not express the views and opinions of The Street Now or its affiliates. Content created by third parties is the sole responsibility of such third parties and its accuracy and completeness are not endorsed or guaranteed by The Street Now. You acknowledge that by providing you with the ability to view third-party content through our site, The Street Now is not undertaking any obligation or liability relating to such third-party content. The Street Now and its affiliates, successors, assigns, officers, directors, partners and employees assume no responsibility or liability that may arise from the third party content, including, but not limited to, claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation. Notwithstanding the foregoing, The Street Now reserves the right to remove third-party content at any time in its sole discretion.